Search Results - "Okily, Mohamed"

Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison by Brunner, Hermine I, Abud-Mendoza, Carlos, Mori, Masaaki, Pilkington, Clarissa A, Syed, Reema, Takei, Syuji, Viola, Diego O, Furie, Richard A, Navarra, Sandra, Zhang, Fengchun, Bass, Damon L, Eriksson, Gina, Hammer, Anne E, Ji, Beulah N, Okily, Mohamed, Roth, David A, Quasny, Holly, Ruperto, Nicolino

“…ObjectiveTo assess the efficacy and safety of belimumab in paediatric versus adult patients with systemic lupus erythematosus (SLE).MethodsWe performed…”
Get full text

CYP3A5 Gene-Guided Tacrolimus Treatment of Living-Donor Egyptian Kidney Transplanted Patients by Mendrinou, Effrosyni, Mashaly, Mohamed Elsayed, Al Okily, Amir Mohamed, Mohamed, Mohamed Elsayed, Refaie, Ayman Fathi, Elsawy, Essam Mahmoud, Saleh, Hazem Hamed, Sheashaa, Hussein, Patrinos, George P

“…Tacrolimus is an approved first-line immunosuppressive agent for kidney transplantations. Part of interindividual and interethnic differences in the response…”
Get full text

Safety and Efficacy of Belimumab in Patients with Lupus Nephritis: Open-Label Extension of BLISS-LN Study by Furie, Richard, Rovin, Brad H, Houssiau, Frédéric, Contreras, Gabriel, Teng, Y K Onno, Curtis, Paula, Green, Yulia, Okily, Mohamed, Madan, Anuradha, Roth, David A

“…In the BLISS-LN study, belimumab improved kidney outcomes in adult patients with active lupus nephritis. This 28-week open-label extension of BLISS-LN assessed…”
Get full text

Efficacy and Safety of Belimumab in Patients With Lupus Nephritis: Subgroup Analyses of a Phase 3 Randomized Trial in the East Asian Population by Yu, Xueqing, Chen, Nan, Xue, Jun, Mok, Chi Chiu, Bae, Sang-Cheol, Peng, Xiaomei, Chen, Wei, Ren, Hong, Li, Xiao, Noppakun, Kajohnsak, Gilbride, Jennifer A., Green, Yulia, Ji, Beulah, Liu, Chang, Madan, Anuradha, Okily, Mohamed, Tang, Chun-Hang, Roth, David A.

“…Belimumab improved kidney outcomes in patients with active lupus nephritis (LN) in BLISS-LN, leading to its approval in the United States and the European…”
Get full text

FC 034SAFETY AND EFFICACY OF INTRAVENOUS BELIMUMAB IN PATIENTS WITH LUPUS NEPHRITIS: A 6-MONTH OPEN-LABEL EXTENSION by Rovin, Brad, Furie, Richard, Houssiau, Frédéric A, Contreras, Gabriel, Teng, Y K O, Curtis, Paula, Madan, Anuradha, Jones-leone, Angela, Gonzalez-Rivera, Tania, Okily, Mohamed, Roth, David

“…Abstract Background and Aims Lupus nephritis (LN) is the most common severe manifestation of systemic lupus erythematosus (SLE), occurring in up to 40% of…”
Get full text

P128 Efficacy of intravenous belimumab in children with systemic lupus erythematosus with markers of high disease activity: across-trial comparison with adult belimumab studies by Bass, Damon L, Okily, Mohamed, Hammer, Anne, Ji, Beulah, Roth, David, Quasny, Holly

“…BackgroundBelimumab is approved as add-on therapy for patients ≥5 years with active, autoantibody-positive systemic lupus erythematosus (SLE).1 The PLUTO trial…”
Get full text

New Fuels, Flame Quenching and Ddt by Shehata, Moustafa Mohamed Attya Okily

“…Two limiting conditions of burning rate are considered, culminating in either flame extinction, or transition to a detonation. A 2D schlieren technique, for…”
Get full text